Latest News

FDA Approves Ofatumumab With Chemo for Relapsed CLL

FDA Approves Ofatumumab With Chemo for Relapsed CLL

The FDA approved ofatumumab (Arzerra) for the treatment relapsed chronic lymphocytic leukemia (CLL).

Biosimilar G-CSF Effective in Preventing Febrile Neutropenia in Sarcoma

Biosimilar G-CSF Effective in Preventing Febrile Neutropenia in Sarcoma

Filgrastim-sndz, a biosimilar product to the G-CSF filgrastim, appears to be effective in the prevention of febrile neutropenia.

Brigatinib NDA Submission Complete for ALK+ Metastatic NSCLC

Brigatinib NDA Submission Complete for ALK+ Metastatic NSCLC

The rolling submission of the New Drug Application to the FDA for brigatinib is complete.

New Scoring System Accurately Identifies Patients Likely to Respond to Treatment

New Scoring System Accurately Identifies Patients Likely to Respond to Treatment

Gene expression that causes chromosomal instability may predict which patients with lung or breast cancer are likely to respond to chemotherapy and radiotherapy.

Higher EUTOS Risk Scores Linked With Delayed Response Rate in CML

Higher EUTOS Risk Scores Linked With Delayed Response Rate in CML

European patients with chronic myeloid leukemia who have high EUTOS risk scores achieved response much later than patients with low EUTOS risk scores.

Retinoic Acid May Aid in Colorectal Cancer Prevention, Treatment

Retinoic Acid May Aid in Colorectal Cancer Prevention, Treatment

Retinoic acid might have a role in suppressing colorectal cancer (CRC).

Caregiver Well-Being Linked With Quality of Cancer Patient Care

Caregiver Well-Being Linked With Quality of Cancer Patient Care

Informal caregiver well-being is associated with patient-perceived quality of care (QOC).

Researchers Determine Best Metrics for Predicting Survival in Ewing Sarcoma

Researchers Determine Best Metrics for Predicting Survival in Ewing Sarcoma

FDG-PET testing that shows early progression of patients with Ewing sarcoma is linked to reduced overall survival.

CTA Treatment Regimen Chart for RCC Updated

CTA Treatment Regimen Chart for RCC Updated

CTA has updated its treatment regimen chart for the treatment of renal cell carcinoma to reflect NCCN Guidelines for Kidney Cancer.

MRD Assessment Improves PFS Prediction for Patients With CLL

MRD Assessment Improves PFS Prediction for Patients With CLL

Minimal residual disease (MRD) assessment improves prediction of progression-free survival for patients with chronic lymphocytic leukemia (CLL).

Higher Facility Volume Linked to Improved OS Among Patients With Anal Cancer

Higher Facility Volume Linked to Improved OS Among Patients With Anal Cancer

Care at radiation oncology centers with a higher volume is associated with improved survival among patients with squamous cell carcinoma of the anal canal.

Greater Perceived Barriers to Aromatase Inhibitors Linked With Non-adherence

Greater Perceived Barriers to Aromatase Inhibitors Linked With Non-adherence

Women with early-stage breast cancer who perceive greater barriers to treatment with aromatase inhibitors (AIs) may be less likely to adhere to regimens.

CTA Treatment Regimen Chart for Head and Neck Cancer Updated

CTA Treatment Regimen Chart for Head and Neck Cancer Updated

CTA has updated its treatment regimen chart for the treatment of head and neck cancer to reflect changes put forth by Version 1.2016 of the NCCN Guidelines for Head and Neck Cancers.

Pacritinib Improves Spleen Volume Recovery in Advanced Myelofibrosis

Pacritinib Improves Spleen Volume Recovery in Advanced Myelofibrosis

Pacritinib, an investigational oral multikinase inhibitor, improves spleen volume reduction among high-risk patients with advanced myelofibrosis.

Alternative Metrics of Response Correlate With OS in FIRE-3 Trial

Alternative Metrics of Response Correlate With OS in FIRE-3 Trial

Alternative metrics of response correlated with the overall survival benefit among patients with RAS wild-type metastatic colorectal cancer (mCRC).

Sentinel Lymph Node Biopsy Recommended for Patients With Sarcoma

Sentinel Lymph Node Biopsy Recommended for Patients With Sarcoma

SLNB are more reliable PET-CT for assessing lymph node metastases among young patients with sarcoma.

HSD3B1 Allele Inheritance Linked With ADT Resistance

HSD3B1 Allele Inheritance Linked With ADT Resistance

The HSD3B1 (1245C) allele is linked to androgen deprivation therapy (ADT) resistance among patients with prostate cancer.

MAPIE Failed to Improve Responses in High-grade Osteosarcoma

MAPIE Failed to Improve Responses in High-grade Osteosarcoma

Addition of ifosfamide and etoposide to adjuvant cisplatin, doxorubicin, and high-dose methotrexate (MAP) did not improve event-free survival.

Continuing Docetaxel Therapy May Improve Survival in Prostate Cancer

Continuing Docetaxel Therapy May Improve Survival in Prostate Cancer

For patients with metastatic castration-resistant prostate cancer (mCRPC), 8 cycles of docetaxel may improve superior overall survival.

Compliance With NCCN Guidelines Benefits Patients With Rectal Cancer

Compliance With NCCN Guidelines Benefits Patients With Rectal Cancer

Adjuvant chemotherapy is beneficial for patients with locally-advanced, postoperative rectal cancer.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters